NDA 207071 · Leo Pharma As
Finacea
Azelaic Acid · Topical
Last checked: Nov 20, 2026Latest source record: Dec 1, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2015
Jul 29, 2015
Approved uses
1
Original approval plus efficacy supplements
Registered trials
37
9 Phase 3, 1 recruiting
FAERS reports
848
450 serious, 84 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 8, 2020.
FINACEA Foam, 15% is indicated for topical treatment of the inflammatory papules and pustules of mild to moderate rosacea. FINACEA Foam is indicated for the topical treatment of inflammatory papules and pustules of mild to moderate rosacea. ( 1 )
Mechanism: The mechanism(s) by which azelaic acid interferes with the pathogenic events in rosacea are unknown.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 29, 2015 Original approval · Type 3 - New Dosage Form ReviewSummary ReviewLabel
1 products under this application
- FINACEA · AZELAIC ACID 15% · AEROSOL, FOAM, TOPICAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Azelaic Acid" as an intervention, any sponsor and status, largest first.
Galderma R&DIndustry
NCT00892281 · 1,421 participants · Start Apr 2009 · Primary completion Oct 2009
Drug: doxycycline (Oracea®) 40 mg modified release as monotherapy; doxycycline (Oracea®) 40 mg modified release as add-on therapy · For: Rosacea
Sites: Lexington, Kentucky
- To Evaluate the Therapeutic Equivalence and Safety in Treatment of Moderate Facial RosaceaPivotal-lookingCompleted
Sun Pharmaceutical Industries, Inc.Industry
NCT03689010 · 1,116 participants · Start Dec 12, 2017 · Primary completion Aug 9, 2018
Drug: Azelaic acid foam 15%; Finacea® (Azelaic acid Foam) 15% and 1 more · For: Rosacea
Sites: Charlotte, North Carolina
- A Study to Evaluate the Safety and Clinical Study of Azelaic Acid Gel 15% in Patients With Moderate Facial RosaceaPivotal-lookingCompleted
Actavis Inc.Industry
NCT02120924 · 1,009 participants · Start Jul 2013 · Primary completion Sep 2014
Drug: Azelaic acid; Vehicle and 1 more · For: Rosacea
Sites: Fremont, California; Santa Monica, California; Brandon, Florida · 30 sites in all
- To Evaluate the Therapeutic Equivalence and Safety of Azelaic Acid 15% Topical GelPivotal-lookingCompleted
Sun Pharmaceutical Industries, Inc.Industry
NCT03094403 · 1,000 participants · Start Jul 1, 2016 · Primary completion Mar 31, 2017
Drug: Azelaic Acid 15% topical gel; Finacea® (azelaic acid) Gel, 15% and 1 more · For: Rosacea
- Safety and Efficacy of Azelaic Acid Foam, 15 % in Papulopustular RosaceaPivotal-lookingCompleted
LEO PharmaIndustry
NCT01555463 · 961 participants · Start Sep 2012 · Primary completion Jan 2014
Drug: Azelaic acid foam, 15% (BAY39-6251); Vehicle foam · For: Papulopustular Rosacea
Sites: Birmingham, Alabama; Fremont, California; Los Angeles, California · 49 sites in all
- A Study to Evaluate Safety and Equivalence of Generic Azelaic Acid Foam and Finacea® Foam in Participants With RosaceaPivotal-lookingCompleted
Actavis Inc.Industry
NCT03287791 · 924 participants · Start Jul 19, 2016 · Primary completion Jun 22, 2017
Drug: Generic Azelaic Acid Foam; Finacea® (Azelaic Acid) Foam and 1 more · For: Rosacea
Sites: Encino, California; La Mesa, California; Brandon, Florida · 26 sites in all
- Comparison of Efficacy and Safety of Azelaic Acid 15% Gel With Its Vehicle in Subjects With Mild to Moderate AcnePivotal-lookingCompleted
LEO PharmaIndustry
NCT00031096 · 879 participants · Start Jan 2002 · Primary completion Jul 2002
Drug: Azelaic Acid Gel 15% (Finacea, BAY39-6251); Vehicle gel (SH H 655 PBA) · For: Acne Vulgaris
Sites: Mobile, Alabama; Boulder, Colorado; Newnan, Georgia · 16 sites in all
- Phase 3 Papulopustular Rosacea StudyPivotal-lookingCompleted
Galderma R&DIndustry
NCT01494467 · 688 participants · Start Dec 2011 · Primary completion Aug 2013
Drug: CD5024; Azelaic acid 15% Gel · For: Papulopustular Rosacea
Sites: Birmingham, Alabama; Mobile, Alabama; Hot Springs, Arkansas · 50 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective154
- pain131
- off label use118
- abdominal pain upper112
- vomiting110
- product use in unapproved indication103
- gastrooesophageal reflux disease102
- paraesthesia102
- migraine101
- memory impairment99
- hypoaesthesia98
- rash97
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 2 |
| 2005 | 1 |
| 2006 | 1 |
| 2008 | 5 |
| 2009 | 3 |
| 2010 | 8 |
| 2011 | 2 |
| 2012 | 2 |
| 2013 | 3 |
| 2014 | 6 |
| 2015 | 20 |
| 2016 | 17 |
| 2017 | 14 |
| 2018 | 27 |
| 2019 | 30 |
| 2020 | 59 |
| 2021 | 68 |
| 2022 | 71 |
| 2023 | 86 |
| 2024 | 134 |
| 2025 | 139 |
| 2026 | 150 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Finacea (Azelaic Acid)
2024 spending
$2.8M
Beneficiaries
3,256
6,032 claims
Per beneficiary
$852
$8.49 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,569,425 |
| 2021 | $2,240,162 |
| 2022 | $2,310,123 |
| 2023 | $2,487,069 |
| 2024 | $2,773,453 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Guidelines of care for the management of acne vulgaris.
Reynolds RV, Yeung H, Cheng CE, et al. · J Am Acad Dermatol 2024 · Practice Guideline, Systematic Review
- Treatment of keratosis pilaris and its variants: a systematic review.
Maghfour J, Ly S, Haidari W, et al. · J Dermatolog Treat 2022 · Systematic Review
- Cosmeceuticals in photoaging: A review.
Chan LKW, Lee KWA, Lee CH, et al. · Skin Res Technol 2024 · Systematic Review
- Perioral dermatitis: Diagnosis, proposed etiologies, and management.
Searle T, Ali FR, Al-Niaimi F · J Cosmet Dermatol 2021 · Systematic Review
- Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha-hydroxy acid) for acne.
Liu H, Yu H, Xia J, et al. · Cochrane Database Syst Rev 2020 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Comparison of the Efficacy of Melasma Treatments: A Network Meta-Analysis of Randomized Controlled Trials.
Liu Y, Wu S, Wu H, et al. · Front Med (Lausanne) 2021 · Systematic Review
Sponsor: Leo Pharma As
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.